Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) is a dermatology therapeutics company focused on developing and commercializing treatments for skin diseases. The company is currently facing challenges in capital efficiency, as indicated by its financial metrics. A key measure of this efficiency is the comparison of Return on Invested Capital (ROIC) to Weighted Average Cost of Capital (WACC).

Verrica's ROIC stands at -65.23%, which is significantly lower than its WACC of 15.85%. This results in a ROIC to WACC ratio of -4.11, highlighting inefficiencies in capital utilization. This negative ratio suggests that the company is not generating sufficient returns on its invested capital, which is a concern for investors.

In comparison, Y-mAbs Therapeutics, Inc. (YMAB) has a ROIC of -27.64% and a WACC of 6.23%, resulting in a ROIC to WACC ratio of -4.44. Although Y-mAbs also has a negative ratio, it is the least negative among the peers, indicating a relatively better capital efficiency compared to Verrica.

Scholar Rock Holding Corporation (SRRK) and Crinetics Pharmaceuticals, Inc. (CRNX) have ROIC to WACC ratios of -15.28 and -9.15, respectively. These figures are more negative than Verrica's, suggesting even greater inefficiencies in their capital utilization. Kezar Life Sciences, Inc. (KZR) also shows a significant negative ratio of -11.75, further emphasizing the challenges faced by these companies in generating returns above their cost of capital.

Overall, while all companies in this analysis are experiencing negative ROIC, Y-mAbs Therapeutics shows the most potential for improvement in capital efficiency. Investors should consider these metrics alongside other financial and strategic factors when evaluating investment opportunities in these companies.